Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study
Not available
Main Authors: | F. Ceccarelli, V. Covelli, G. Olivieri, F. Natalucci, C. Alessandri, F. Conti |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2022-09-01
|
Series: | Reumatismo |
Online Access: | https://www.reumatismo.org/index.php/reuma/article/view/1491 |
Similar Items
-
Are Tattoos Safe in Patients With Systemic Lupus Erythematosus? Results From a Single-Center Study
by: Francesco Natalucci, et al.
Published: (2024-10-01) -
P60 Performance of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients
by: Fabrizio Conti, et al.
Published: (2024-03-01) -
Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity
by: Fulvia Ceccarelli, et al.
Published: (2023-01-01) -
P115 Belimumab treatment rapidly restores B cell homeostasis and reduces atypical T-bet+ B cell expansion in patients with systemic lupus erythematosus
by: Fabrizio Conti, et al.
Published: (2024-03-01) -
Systemic Lupus Erythematosus Following COVID-19 Vaccination
by: Anna Farazilah Mohd Salleh, et al.
Published: (2022-10-01)